Skip to main content
. 2021 Sep 9;7(3):89–91. doi: 10.1016/j.afos.2021.09.002

Table 1.

Cardiovascular safety of romosozumab report compared to Shiga Cohort Study in Japan.

Stroke ICD
Romosozumab [18] 0.164 0.1007
Shiga Cohort [19,20] 0.40 0.17

Incidence with 100 person-years reported on reference numbers of 18, 19, and 20.

ICD, ischemic cardiovascular diseases.